Abstract
Introduction

Imatinib targets the constitutively active BCR-ABL tyrosine kinase in chronic myeloid leukaemia (CML) and has become standard treatment based on excellent responses achieved in clinical trials
. However, imatinib resistance can occur through several mechanisms including BCR-ABL kinase domain mutations, amplification, overexpression and clonal evolution [4] . Successful strategies to overcome imatinib resistance include dose escalation or the use of second-generation BCR-ABL kinase inhibitors including nilotinib, dasatinib or bosutinib [5] [6] [7] . However, none of these agents are effective in CML cells harbouring the 'gatekeeper' T315I mutation at the base of the ATP binding pocket, which occurs in up to 20% of imatinib resistance cases.
The discovery that Aurora kinases were abnormally expressed in malignancies including leukaemia prompted the development of agents that inhibit their activity [8] [9] [10] . The panAurora kinase inhibitors, MK-0457 and danusertib have shown pre-clinical and clinical activity against CML harbouring the BCR-ABL T315I mutation [10] [11] [12] [13] . The antileukaemia efficacy of MK-0457 in CML was originally attributed to direct inhibition of BCR-ABL kinase activity [14, 15] 
. However, a recent study demonstrated that the efficacy of MK-0457 at clinically relevant doses in BCR-ABL
ϩ cells was primarily due to inhibition of Aurora, rather than BCR-ABL, kinase activity [16] . [17] [18] [19] . The (Fig. 3C) . We conducted similar experiments to also confirm that the concentration of MLN8237 that we utilized for our experiments with primary patient cells did not significantly affect BCR-ABL kinase activity (Fig. 3D) . (Fig. 5A) . [19] . (Fig. 5C, second from the left) . Although this outcome is primarily associated with inhibition of Aurora B, cytokinesis failure can occur upon inhibition of Aurora A as well [18] . Other functional consequences of Aurora A inhibition that were prominent in the MLN8237-treated tumours (Fig. 5C (Fig. 5D) . (Fig. 6A) . To confirm that this reduction in Apollon expression is a direct consequence of Aurora A kinase inhibition, we used siRNA to knockdown Aurora A expression. This led to a very significant reduction in the levels of Apollon (Fig. 6B) . This effect does not appear to be a general feature of mitotic disruption as treatment with nocodazole and vincristine did not significantly decrease Apollon expression and therefore rather suggests a link between Aurora A activity and Apollon expression (Fig. 6C) . (Fig. 6D) . Nilotinib induced significantly greater levels of apoptosis in LAMA 84 cells treated with Apollon-targeted siRNA compared to non-targeted controls (Fig. 6D) 
Statistical analyses
MLN8237 has in vitro and in vivo antiproliferative effects in imatinib-resistant cells and its activity is unaffected by impairment of p53 function
Co
MLN8237 cooperates with nilotinib to reduce tumour burden in K562 xenografts
K562 xenograft studies were carried out to investigate the in vivo therapeutic potential of the combination of MLN8237 and nilotinib. Both agents had substantial effects on tumour burden and the combination resulted in significantly greater tumour growth inhibition than what was achieved by either agent alone
Furthermore, the combination was well tolerated and only a modest, statistically insignificant loss in body weight was observed in the treated groups (Fig. 5A). Notably, the single agent in vivo effects of MLN8237 were more impressive in this K562 experiment than what we observed in our studies with the murine Ba/F3 models (Fig. 2C). Given that human and murine Aurora A genes share 79% sequence homology and that MLN8237 was specifically designed to target human Aurora A kinase activity, it is possible that species-specific differences in the potency of MLN8237-mediated kinase inhibition could have contributed to this phenomenon. Haematoxylin and eosin staining was used to visualize the architecture of tumours from each treatment group and revealed
Fig. 2 Continued substantial differences in the morphology of single agent and combination-treated tumours. In particular, the tumours treated with the combination of MLN8237 and nilotinib displayed evidence of stromal disruption and high levels of cell death with very few intact CML cells remaining (Fig. 5B). This suggests that remaining tumours from combination-treated mice were largely comprised Matrigel and non-viable cells/tissue and also highlights the potential therapeutic benefit provided by the combination over single agent treatments.
Treatment with MLN8237 in vivo leads to a morphological phenotype consistent with inhibition of Aurora A kinase
Consistent with our in vitro data, the number of multi-nucleated cells visible in the MLN8237-treated tumours stained with haematoxylin and eosin was increased as compared with vehicle control indicating that MLN8237 causes cells to exit mitosis without completing cytokinesis, a process known as mitotic slippage
Table 1 Effects of MLN8237 in BCR-ABL + cells
Apoptosis
Cell cycle
